Straits Times Index
3,336.59 +13.21 (+0.40%) S&P 500
5,277.51 +42.03 (+0.80%) Dow
38,686.32 +574.82 (+1.51%) Nasdaq
16,735.02 -2.08 (-0.01%) Bitcoin USD
67,863.34 +225.06 (+0.33%) CMC Crypto 200
1,466.91 +38.34 (+2.68%)
Skye Bioscience, Inc. (SKYE)
After hours:
| Previous close | 11.65 |
| Open | 11.88 |
| Bid | 11.44 x 100 |
| Ask | 11.96 x 100 |
| Day's range | 10.79 - 11.93 |
| 52-week range | 1.44 - 19.41 |
| Volume | |
| Avg. volume | 50,214 |
| Market cap | 325.868M |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.23 |
| Earnings date | 07 Aug 2024 - 11 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
Simply Wall St.Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake
Key Insights Skye Bioscience's significant private equity firms ownership suggests that the key decisions are...
GlobeNewswireSkye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with novel mechanisms of action for other ocular pathologiesSAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the
- GlobeNewswire
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington. Details of the presentations are as follow
